N-ethyl-N-methyl-2-[5-(methylaminomethylsulfonylmethyl)-1H-indol-3-yl]ethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-ethyl-N-methyl-2-[5-(methylaminomethylsulfonylmethyl)-1H-indol-3-yl]ethanamine
• 化学式: C₁₆H₂₅N₃O₂S
• 分子量: 323.5
• InChiKey: FBTKDISNBCMQCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  73.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES
  申请人：CELLIXBIO PRIVATE LIMITED

  公开号：US20150291590A1

  公开（公告）日：2015-10-15

  The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III; and methods for treating or preventing metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of phenylketonuria, cardiovascular disease, autism, ADHD, hypertension, endothelial dysfunction and chronic kidney disease.

  该发明涉及公式I、公式II和公式III的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I、公式II或公式III化合物的有效量的药物组合物；以及用于治疗或预防代谢性疾病的方法可以制备成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂。这些组合物可用于治疗苯丙酮尿症、心血管疾病、自闭症、注意力缺陷多动障碍、高血压、内皮功能障碍和慢性肾脏疾病。
• COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES
  申请人：KANDULA Mahesh

  公开号：US20150152060A1

  公开（公告）日：2015-06-04

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of migraine and neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, migraine, Post Herpetic Neuralgia, Acute and Chronic Pain, Alzheimer's disease, Creutzfeld Disease, familial amyloid polyneuropathy, parkinson's disease, fibromyalgia syndrome.

  本发明涉及公式I化合物或其药学上可接受的盐，以及其多晶形态、溶剂化物、对映体、立体异构体和水合物。该药物组合物包括有效量的公式I化合物，并可制成口服、颊下、直肠、局部、经皮、经黏膜、静脉、肌肉注射、糖浆或注射剂的药物制剂。这样的组合物可以用于治疗癫痫、偏头痛、带状疱疹后神经痛、急性和慢性疼痛、阿尔茨海默病、克氏肌萎缩症、家族性淀粉样多神经病、帕金森病、纤维肌痛综合征等神经系统疾病的治疗。
• COMPOSITIONS AND METHODS FOR THE TREATMENT ANGINA AND CARDIOVASCULAR CONDITIONS
  申请人：Cellixbio Private Limited

  公开号：US20150148352A1

  公开（公告）日：2015-05-28

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of angina and cardiovascular conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic aneurysm, angina, atherosclerosis, cerebrovascular accident (stroke), cerebrovascular disease, congestive heart failure, coronary artery disease, myocardial infarction (heart attack), peripheral vascular disease, aortic dissection, aortic stenosis, arrhythmia (irregular heartbeat), atrial fibrillation, cardiomyopathy, chest pain, claudication, congenital heart disease.

  本发明涉及公式I化合物或其药学上可接受的盐，以及其多晶形、溶剂化合物、对映体、立体异构体和水合物。该药物组合物包括有效量的公式I化合物，并可制备用于口服、颊下、直肠、局部、经皮、经黏膜、静脉、肌肉注射、糖浆或注射的药物组合物，用于治疗心绞痛和心血管疾病的方法。这些组合物可用于治疗慢性动脉瘤、心绞痛、动脉粥样硬化、脑血管意外（中风）、脑血管疾病、充血性心力衰竭、冠状动脉疾病、心肌梗死（心脏病发作）、周围血管疾病、主动脉夹层、主动脉瓣狭窄、心律失常（心跳不规则）、心房颤动、心肌病、胸痛、跛行、先天性心脏病。
• US9187427B2
  申请人：——

  公开号：US9187427B2

  公开（公告）日：2015-11-17
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE LA MIGRAINE ET DE MALADIES NEUROLOGIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014020480A2

  公开（公告）日：2014-02-06

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of migraine and neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, migraine, Post Herpetic Neuralgia, Acute and Chronic Pain, Alzheimer's disease, Creutzfeld Disease, familial amyloid polyneuropathy, parkinson's disease, fibromyalgia syndrome.